January 06, 2009; 72 (1) Articles
Oral fingolimod (FTY720) in multiple sclerosis
Two-year results of a phase II extension study
P. O'Connor, G. Comi, X. Montalban, J. Antel, E. W. Radue, A. de Vera, H. Pohlmann, L. Kappos
First published January 2, 2009, DOI: https://doi.org/10.1212/01.wnl.0000338569.32367.3d
P. O'Connor
G. Comi
X. Montalban
J. Antel
E. W. Radue
A. de Vera
H. Pohlmann
Oral fingolimod (FTY720) in multiple sclerosis
Two-year results of a phase II extension study
P. O'Connor, G. Comi, X. Montalban, J. Antel, E. W. Radue, A. de Vera, H. Pohlmann, L. Kappos
Neurology Jan 2009, 72 (1) 73-79; DOI: 10.1212/01.wnl.0000338569.32367.3d
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 72 no. 1 73-79
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published January 2, 2009.
Copyright & Usage:
© 2009
Author Disclosures
- P. O'Connor, MD,
- G. Comi, MD,
- X. Montalban, MD,
- J. Antel, MD,
- E. W. Radue, MD,
- A. de Vera, MD,
- H. Pohlmann, MSc,
- L. Kappos, MD and
- For the FTY720 D2201 Study Group*
- P. O'Connor, MD,
- G. Comi, MD,
- X. Montalban, MD,
- J. Antel, MD,
- E. W. Radue, MD,
- A. de Vera, MD,
- H. Pohlmann, MSc,
- L. Kappos, MD and
- For the FTY720 D2201 Study Group*
- From St. Michael's Hospital (P.O.), Toronto, ON, Canada; Ospedale San Raffaele (G.C.), Milan, Italy; University Hospital Edif. EUI (X.M.), Barcelona, Spain; Montreal Neurological Institute (J.A.), Montreal, QC, Canada; MS MRI Evaluation Centre (E.W.R.) and Neurology and Department of Biomedicine (L.K.), University Hospital, Basel; and Novartis Pharma AG (A.d.V., H.P.), Basel, Switzerland.
- Address correspondence and reprint requests to Dr. Paul O'Connor, St. Michael's Hospital, Toronto, ON, Canada oconnorp{at}smh.toronto.on.ca
Article usage
Cited By...
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan